This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Akero became a wholly owned subsidiary of Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
